Key Highlights

  • Net income was USD 19.2 million, or USD 0.26 per diluted share, in the third quarter of 2026, filed by Zevra Therapeutics (NASDAQ:ZVRA) on November 3, 2026, against a loss of USD 0.5 million a year earlier.
  • Net Revenue rose to USD 37.8 million from USD 26.1 million, while income from operations rose to USD 11.6 million from USD 4.1 million.
  • Nine-month revenue reached USD 113.6 million compared with USD 72.3 million, and a separate USD 43.3 million gain on the sale of future royalties, intellectual property and other Assets was booked.
  • Long-term Debt was zero at September 30, 2026 against USD 61.9 million at year end, and cash plus investments totaled about USD 270.9 million by simple arithmetic.

From a Small Loss to USD 19.2 Million of Net Income

Zevra Therapeutics (NASDAQ:ZVRA), a company that markets products including MIPLYFFA and OLPRUVA, filed its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. Revenue was USD 37.8 million, about 45% higher than the USD 26.1 million of the third quarter of 2025, simple arithmetic on the two reported figures. Income from operations more than doubled to USD 11.6 million, and pre-tax income was USD 19.7 million with income tax expense of only USD 0.5 million. The reviewed extract contains financial statements but not management's discussion of what drove sales, so product-level detail is not available here.

Operating Profit Versus Non-Cash Gains

Not all of the improvement came from operations. Other income included a USD 5.1 million gain on the Fair Value of a Warrant and contingent value right liability, against a USD 5.5 million loss a year earlier, plus USD 3.0 million of interest and other income. Interest expense was nil after the debt was repaid, versus USD 2.1 million. Costs rose more slowly than sales: cost of product revenue was USD 1.8 million, Research and Development rose to USD 4.9 million from USD 3.4 million, and selling, general and administrative expense rose to USD 19.1 million from USD 16.9 million. Net Income of USD 19.2 million therefore exceeds Operating Income of USD 11.6 million by USD 7.6 million, mainly from items outside operations.

Nine-Month Comparisons Distorted by One-Time Items

Nine-month net income was USD 65.9 million, below USD 71.1 million a year earlier, even though revenue rose. The 2025 period included a USD 148.3 million gain on a priority review voucher sale offset by a USD 58.7 million intangible asset impairment, while 2026 includes the USD 43.3 million asset sale gain, a USD 2.8 million loss on debt extinguishment and a USD 7.2 million loss on a derivative liability. Cash and cash equivalents were USD 122.1 million, up from USD 62.4 million, and Equity was USD 238.9 million. The company's risk list covers commercialization, regulatory approvals, clinical trial timing and the ability to raise funds, so the durability of profit depends on sales growth continuing.

Where Things Stand

Zevra Therapeutics (NASDAQ:ZVRA) swung to profit because revenue grew about 45% against costs that rose far more slowly, and a debt repayment removed interest expense. About USD 7.6 million of net income came from items outside operations, mainly a non-cash Liability Revaluation and Investment income, so operating income of USD 11.6 million is the cleaner gauge. The Balance Sheet is strong, with no long-term debt and about USD 270.9 million in cash and investments by simple arithmetic. The next 10-Q and any regulatory or product updates will show whether the sales trend holds.